Intra Cellular Therapies | ITCI - Stock


Intra Cellular Therapies reported $26.28M in Stock for its fiscal quarter ending in December of 2024.



Stock Change Date
Acadia Pharmaceuticals USD 31.57M 3.1M Mar/2026
ALKERMES USD 336.7M 140.08M Mar/2026
BioCryst Pharmaceuticals USD 5.98M 587K Mar/2026
Biogen USD 1.95B 219.1M Mar/2026
Bristol-Myers Squibb USD 2.76B 66M Mar/2026
Esperion Therapeutics USD 104.21M 915K Mar/2026
Gilead Sciences USD 1.91B 140M Mar/2026
Halozyme Therapeutics USD 155.47M 21.01M Mar/2026
J&J USD 14.58B 392M Mar/2026
Nektar Therapeutics USD 14.46M 1.78M Jun/2024
Neurocrine Biosciences USD 64.5M 4.5M Mar/2026
Novartis USD 6.42B 114M Sep/2025
RedHill Biopharma USD 3.17M 482K Jun/2025
Supernus Pharmaceuticals USD 110.77M 1.71M Mar/2026
United Therapeutics USD 178.3M 4.8M Mar/2026
Vanda Pharmaceuticals USD 1.85M 190K Dec/2025